The primary treatment approach for retinal diseases, particularly for wet AMD, has oscillated between medical management (in-office laser treatment, injections, and systemic therapies) and surgical management (subretinal choroidal neovascular membrane removal, macular translocation, and surgical transplantation of the retinal pigment epithelium [RPE]). The introduction of anti-VEGF therapy effectively sidelined the surgical management of wet AMD. The widely adopted off-label use of intravitreal bevacizumab (Avastin, Genentech) drove the treatment of wet AMD further into the medical realm.

A similar treatment trend is occurring with diabetic retinopathy (DR), with a shift from primary surgical correction of proliferative DR complications, such as vitreous hemorrhage and tractional retinal detachments, toward prevention of these complications altogether using anti-VEGF therapies.

PANORAMA is a phase 3 clinical trial assessing patients with moderately severe to severe nonproliferative DR without center-involving diabetic macular edema treated with loading doses of aflibercept (Eylea, Regeneron) followed by fixed-interval injections or sham injections. At years 1 and 2, fewer patients in the aflibercept arms developed a vision-threatening complication due to proliferative DR, including vitreous hemorrhage and tractional retinal detachments, either of which would require surgical intervention.

Potential in-office intravitreal anti-VEGF therapies now in phase 2 and 3 trials include faricimab (Genentech/Roche), conbercept (Chengdu Kanghong Biotech), OPT-302 (Opthea), KSI-301 (Kodiak), and GB-102 (Graybug Vision. These promise increased durability or sustained release for the treatment of neovascular AMD and DR.

(Wet AMD Surgical Innovations)

The medical retina pipeline is robust, but so is the surgical pipeline—and it’s already proving fruitful. In October, the FDA approved the port delivery system with ranibizumab (Susvimo, Genentech/Roche), expanding our clinical armamentarium for wet AMD. Several other innovations on the horizon have the potential to revolutionize the treatment of retinal disease, and many of them harness the power of gene therapy.

How it Started

Retina surgery has changed dramatically since Retina Today’s first issue. Surgeons in 2006 were still hotly debating the utility of 25-gauge surgery, with some concluding that the time saved by the sutureless technique was lost because of the longer surgery time.

Autologous transplantation of retinal pigment epithelium remained a go-to treatment option for many patients with AMD, and meeting lecturers were still trying to figure out when it was appropriate to forego anti-VEGF therapy in favor of the tried-and-true subretinal surgical removal of neovascular membranes.

Oh, and that implantable miniature telescope (SING IMT, Samsara) that’s now in its second generation? The FDA’s Ophthalmic Devices Advisory Panel suggested it was “not approvable” in July 2006.
therapy to provide continuous dosing of medications.

**RGX-314 (Regenxbio)** is a novel adeno-associated virus serotype 8 vector used to deliver a gene encoding for an anti-VEGF antigen-binding fragment. It is designed to produce continuous anti-VEGF therapy to treat wet AMD and DR. Subretinal delivery of this therapy requires a pars plana vitrectomy (PPV) followed by creation of a subretinal bleb using a 41-gauge needle (Figure). All six patients in cohort 3 enrolled in the long-term follow-up study, and treatment effect was demonstrated over 3 years with a mean BCVA improvement of +12 letters from baseline. Cohort 3 showed a 66.7% decrease in the rate of annual anti-VEGF injections compared with the 12 months prior to RGX-314 therapy. Cohorts 4 and 5 showed a 58.3% and 81.2% reduction of anti-VEGF injections, respectively, at 1.5 years. Both cohorts experienced stable vision and decreased retinal thickness.

Notably, no immunologic reactions, drug-related ocular inflammation, or postsurgical inflammation was seen beyond what is anticipated after routine PPV. However, retinal pigmentary changes in 69% of patients necessitated a change in the surgical technique to help prevent macular changes.

The phase 2b/3 ATMOSPHERE trial is now recruiting and will randomly assign 300 pseudophakic patients with wet AMD to receive subretinal RGX-314 or monthly intravitreal ranibizumab. The primary endpoint is the change in visual acuity compared with monthly ranibizumab at week 54.

Oscillating back to medical management, the phase 2 AAVIATE and ALTITUDE trials are assessing in-office suprachoroidal injection of RGX-314.

**GEOGRAPHIC ATROPHY SURGICAL INNOVATIONS**

Geographic atrophy (GA) is a disease for which an efficacious surgical intervention might have the greatest impact. Future surgical therapies for GA will rely on early detection followed either by gene therapy to slow the progression of GA or cellular therapy to replace damaged RPE cells.

In the HORIZON and EXPLORE phase 2 clinical trials, **GT005 (Gyroscope Therapeutics)** is surgically injected into the subretinal space via a pars plana approach. GT005 is an adeno-associated virus vector designed to deliver a gene encoding for complement factor I. The FOCUS phase 1/2 is a safety and dose-finding study where GT005 is delivered subretinally using either a transvitreal approach (cohorts 1–4) or the Orbit Subretinal Delivery Device System (Gyroscope Therapeutics) where GT005 is delivered via suprachoroidal cannulation (cohorts 5–7). Interim data showed that GT005 was well tolerated at all doses and treatment resulted in sustained increases in visual acuity compared with monthly ranibizumab at week 54.

The FOCUS phase 1/2 is complete with 2-year data from all five dose cohorts. Patients in cohorts 3, 4, and 5 showed improved vision and a significant reduction in the need for supplemental anti-VEGF injections. Anti-VEGF protein levels were dose-dependent and durable for at least 2 years. All six patients in cohort 3 enrolled in the long-term follow-up study, and treatment effect was demonstrated over 3 years with a mean BCVA improvement of +12 letters from baseline. Cohort 3 showed a 66.7% decrease in the rate of annual anti-VEGF injections compared with the 12 months prior to RGX-314 therapy. Cohorts 4 and 5 showed a 58.3% and 81.2% reduction of anti-VEGF injections, respectively, at 1.5 years. Both cohorts experienced stable vision and decreased retinal thickness.

Notably, no immunologic reactions, drug-related ocular inflammation, or postsurgical inflammation was seen beyond what is anticipated after routine PPV. However, retinal pigmentary changes in 69% of patients necessitated a change in the surgical technique to help prevent macular changes.

The phase 2b/3 ATMOSPHERE trial is now recruiting and will randomly assign 300 pseudophakic patients with wet AMD to receive subretinal RGX-314 or monthly intravitreal ranibizumab. The primary endpoint is the change in visual acuity compared with monthly ranibizumab at week 54.

Oscillating back to medical management, the phase 2 AAVIATE and ALTITUDE trials are assessing in-office suprachoroidal injection of RGX-314.

**GEOGRAPHIC ATROPHY SURGICAL INNOVATIONS**

Geographic atrophy (GA) is a disease for which an efficacious surgical intervention might have the greatest impact. Future surgical therapies for GA will rely on early detection followed either by gene therapy to slow the progression of GA or cellular therapy to replace damaged RPE cells.

In the HORIZON and EXPLORE phase 2 clinical trials, **GT005 (Gyroscope Therapeutics)** is surgically injected into the subretinal space via a pars plana approach. GT005 is an adeno-associated virus vector designed to deliver a gene encoding for complement factor I. The FOCUS phase 1/2 is a safety and dose-finding study where GT005 is delivered subretinally using either a transvitreal approach (cohorts 1–4) or the Orbit Subretinal Delivery Device System (Gyroscope Therapeutics) where GT005 is delivered via suprachoroidal cannulation (cohorts 5–7). Interim data showed that GT005 was well tolerated at all doses and treatment resulted in sustained increases in visual acuity compared with monthly ranibizumab at week 54.

The FOCUS phase 1/2 is complete with 2-year data from all five dose cohorts. Patients in cohorts 3, 4, and 5 showed improved vision and a significant reduction in the need for supplemental anti-VEGF injections. Anti-VEGF protein levels were dose-dependent and durable for at least 2 years. All six patients in cohort 3 enrolled in the long-term follow-up study, and treatment effect was demonstrated over 3 years with a mean BCVA improvement of +12 letters from baseline. Cohort 3 showed a 66.7% decrease in the rate of annual anti-VEGF injections compared with the 12 months prior to RGX-314 therapy. Cohorts 4 and 5 showed a 58.3% and 81.2% reduction of anti-VEGF injections, respectively, at 1.5 years. Both cohorts experienced stable vision and decreased retinal thickness.

Notably, no immunologic reactions, drug-related ocular inflammation, or postsurgical inflammation was seen beyond what is anticipated after routine PPV. However, retinal pigmentary changes in 69% of patients necessitated a change in the surgical technique to help prevent macular changes.

The phase 2b/3 ATMOSPHERE trial is now recruiting and will randomly assign 300 pseudophakic patients with wet AMD to receive subretinal RGX-314 or monthly intravitreal ranibizumab. The primary endpoint is the change in visual acuity compared with monthly ranibizumab at week 54.

Oscillating back to medical management, the phase 2 AAVIATE and ALTITUDE trials are assessing in-office suprachoroidal injection of RGX-314.

**GEOGRAPHIC ATROPHY SURGICAL INNOVATIONS**

Geographic atrophy (GA) is a disease for which an efficacious surgical intervention might have the greatest impact. Future surgical therapies for GA will rely on early detection followed either by gene therapy to slow the progression of GA or cellular therapy to replace damaged RPE cells.

In the HORIZON and EXPLORE phase 2 clinical trials, **GT005 (Gyroscope Therapeutics)** is surgically injected into the subretinal space via a pars plana approach. GT005 is an adeno-associated virus vector designed to deliver a gene encoding for complement factor I. The FOCUS phase 1/2 is a safety and dose-finding study where GT005 is delivered subretinally using either a transvitreal approach (cohorts 1–4) or the Orbit Subretinal Delivery Device System (Gyroscope Therapeutics) where GT005 is delivered via suprachoroidal cannulation (cohorts 5–7). Interim data showed that GT005 was well tolerated at all doses and treatment resulted in sustained increases in visual acuity compared with monthly ranibizumab at week 54.

The FOCUS phase 1/2 is complete with 2-year data from all five dose cohorts. Patients in cohorts 3, 4, and 5 showed improved vision and a significant reduction in the need for supplemental anti-VEGF injections. Anti-VEGF protein levels were dose-dependent and durable for at least 2 years. All six patients in cohort 3 enrolled in the long-term follow-up study, and treatment effect was demonstrated over 3 years with a mean BCVA improvement of +12 letters from baseline. Cohort 3 showed a 66.7% decrease in the rate of annual anti-VEGF injections compared with the 12 months prior to RGX-314 therapy. Cohorts 4 and 5 showed a 58.3% and 81.2% reduction of anti-VEGF injections, respectively, at 1.5 years. Both cohorts experienced stable vision and decreased retinal thickness.

Notably, no immunologic reactions, drug-related ocular inflammation, or postsurgical inflammation was seen beyond what is anticipated after routine PPV. However, retinal pigmentary changes in 69% of patients necessitated a change in the surgical technique to help prevent macular changes.

The phase 2b/3 ATMOSPHERE trial is now recruiting and will randomly assign 300 pseudophakic patients with wet AMD to receive subretinal RGX-314 or monthly intravitreal ranibizumab. The primary endpoint is the change in visual acuity compared with monthly ranibizumab at week 54.

Oscillating back to medical management, the phase 2 AAVIATE and ALTITUDE trials are assessing in-office suprachoroidal injection of RGX-314.
vitreous complement factor I levels in the majority of patients. There have been no clinically significant GT005-related ocular inflammatory events.

A phase 1/2a clinical trial at the National Eye Institute is evaluating the feasibility of subretinal transplantation of induced pluripotent stem cell–derived RPE. Induced pluripotent stem cells are generated from a GA patient’s somatic cells, differentiated into RPE cells, and grown on a monolayer of biodegradable polylysine-c-lysine acid scaffold. The cells are then transplanted into the subretinal space of the same patient with the goal of rescuing the overlying neurosensory retina from further degeneration. A PPV is required, and the transplant is placed through a planned retinotomy, requiring a gas tamponade.

OpRegen (Lineage Cell Therapeutics) uses human embryonic stem cell–derived RPE cells that are transplanted subretinally in patients with GA. The phase 1/2a trial includes four cohorts, the first three of which are complete. Data show that the treatment was well tolerated with no unexpected adverse events and no inflammatory events. At 15 months, treated eyes had a statistically significant improvement in BCVA compared with the fellow eyes. Early OCT imaging suggests the possible resolution of incomplete RPE and outer retinal atrophy after treatment.

**FINAL THOUGHTS**

Inevitably, the primary treatment of retinal diseases will continue to oscillate between medical and surgical interventions as new approaches emerge. We have an arsenal of therapeutics, many of which are surgical, on the horizon that may provide a longer duration of therapy and perhaps even permanent solutions to these challenging diseases.

---


---

**THE RETINA PIPELINE**

---

**JORDAN D. DEANER, MD**

- Vitreoretinal Surgery Fellow, Duke University Eye Center, Durham, North Carolina
- jordan.deaner@duke.edu
- Financial disclosure: Honoraria (Alimera Sciences)

---

**LEILA VAIZOVIC, MD, FASRS**

- Director, Duke Surgical Vitreoretinal Fellowship Program, Duke University Eye Center, Durham, North Carolina
- Director, Duke Eye Center Continuing Medical Education, Duke University Eye Center, Durham, North Carolina
- Associate Professor of Ophthalmology, Adult and Pediatric Vitreoretinal Surgery and Diseases, Duke University Eye Center, Durham, North Carolina
- leila.vaizovic@duke.edu
- Financial disclosure: Consultant (Alcon, Allerma Sciences, Allergan, Aerie, Bausch + Lomb, BVI, DORC, Guidepoint, Gyroscope/Orbit Biomedical, Janssen Pharmaceutical, Novartis, Oculus Surgical, Regenxbio, Roche/Genetech, Second Sight), Honoraria (Evolve Medical Education), Investigator (AGTC, Allcon, Aldeyra, Heidelberg Engineering, Novartis, Regenxbio, Roche/Genetech, Second Sight); Research Grants (Gyroscope/Orbit Biomedical, Heidelberg Engineering)